Overview severe Valuation disconnect from fundamentals
Stock at $84.64 vs ACCE fair value $25.00. Forward P/E 126.6, P/S 55.3 with negative net margin -14.2% and negative ROE -4.2%. Unsustainable multiple.
high Earnings collapse and negative FCF
EPS down 87.5% YoY, Q4 surprise -200%. Operating margin -6.4%, net margin -14.2%. FCF negative $5.4M. Profitability deteriorating despite 33.7% revenue growth.
high Insider heavy selling
Last 10 disclosures: $12.02M in insider sales, zero buys. Insiders liquidating while stock trades at 3.4x ACCE fair value.
moderate Score volatility and short interest
ACCE score jumped +15 points in 90 days (38 to 53), driven by Quality rebound. Short interest 16.5% signals skepticism. Score remains below 60 (weak).
AI research notes AI-assisted· How I use AI Written Oct 11, 2026 · figures from 2026-05-31 · prices to Oct 23, 2026 Why it could do well
Revenue grew 33.7% year over year with a 24.7% five-year average, showing sustained demand. Revenue growth, year over year +33.7% · 10-K FY2026 Revenue growth, 5-year average per year +24.7% · 10-K FY2026
Latest earnings beat expectations by 183.3%, signaling operational improvement and analyst underestimation. Latest earnings per share surprise +183.3% (EPS 0.05 vs -0.06 expected) · Earnings 14 Jul
Why it could disappoint
Company lost money with negative 14.2% net margin and negative 4.2% return on equity. Net margin -14.2% · 10-K FY2026 Return on equity (ROE) -4.2% · 10-K FY2026
Forward P/E of 126.6x is extremely expensive relative to current profitability and cash generation. Forward P/E 126.6x · Prices 9 Oct
Free cash flow was negative $5M last twelve months while share count diluted 3.7% annually. Free cash flow, last 12 months -$5M · 10-K FY2026 Diluted share count change, last fiscal year +3.7% · 10-K FY2026
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results Nov 2, 2026 We update the fair value about 2 days after the results, once the new figures are filed. Google Walk me through this stock Plain-English pros, cons, and what to watch. Pro feature.
PRO
Valuation INVESTOR Where AEHR's valuation models land
Model fair value
about $74.90
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality INVESTOR Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+ A plain reason under every score+ Conviction breakdown and growth / value / quality / momentum scores+ Score history: how each score moved over time
Analysts Wall Street consensus Bullish 100% buy · 6 covering analysts
● Strong buy 6● Buy 0● Hold 0● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
+ Price-target low / average / high vs the current price, with implied upside+ Forward revenue and EPS consensus by fiscal year+ ACCE fair-value models lined up against the Street
Smart Money PRO In one line Trades are only made public after a delay. We show the delay so you know how old the news is.
Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Smart money tracking PRO FEATURE
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
+ Quarter-over-quarter institutional position changes+ Every insider and Congress trade, with how late it was disclosed+ Active 13D activist filings and top holders
News and Record Press releases mentioning this company
What if I had held it? Simulated 5-year total return vs SPY, and score-threshold backtests Show
Recent ACCE blog coverage Recommendation history, last 12 months Date Type New Previous Price 17 Oct 2026, 00:00 CEST ACCE price target $53.00 $25.00 $60.60 6 May 2026, 00:00 CEST ACCE price target $25.00 first publication
This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.
Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.
Valuation horizon: 12 months from the publication date.
Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.